Metastasis‐enhancing protein KITENIN confers temozolomide resistance on glioblastoma with unmethylated MGMT via upregulation of cancer stem cell makers

Saved in:
Bibliographic Details
Published inClinical and translational medicine Vol. 14; no. 8; pp. e1804 - n/a
Main Authors Ahn, Eun‐Jung, Kim, Yeong Jin, Akanda, Md Rashedunnabi, Oh, Se‐Jeong, Jung, Tae‐Young, Jung, Shin, Lee, Jae‐Hyuk, Kim, Sung Sun, Jeong, Yong Yeon, Ha, Hyung‐Ho, Hyun, Hoon, Kim, Hangun, Rhee, Joon Haeng, Kim, Kyung Keun, Lee, Kyung‐Hwa, Moon, Kyung‐Sub
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.08.2024
Wiley
Subjects
Antineoplastic Agents, Alkylating - pharmacology
Antineoplastic Agents, Alkylating - therapeutic use
Cancer
Dehydrogenases
DNA methylation
DNA Modification Methylases - genetics
DNA Modification Methylases - metabolism
DNA repair
DNA Repair Enzymes - genetics
DNA Repair Enzymes - metabolism
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Glioblastoma - drug therapy
Glioblastoma - genetics
Glioblastoma - metabolism
Glioblastoma - pathology
Glioma
Humans
Localization
Metastasis
Neoplastic Stem Cells - drug effects
Neoplastic Stem Cells - metabolism
Potassium
Proteins
Stem cells
Survival analysis
Temozolomide - pharmacology
Temozolomide - therapeutic use
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Up-Regulation - drug effects
Online AccessGet full text

Cover

More Information
Bibliography:Eun‐Jung Ahn and Yeong Jin Kim equally contributed to this work (co‐first authors).
content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:2001-1326
2001-1326
DOI:10.1002/ctm2.1804